Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis

Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis

Abstract In the CheckMate 651 study, nivolumab plus ipilimumab versus EXTREME (cisplatin/carboplatin + cetuximab + fluorouracil) regimen was compared for effectiveness. It is not known whether these immunotherapy agents are cost-effective for recurrent or metastatic squamous cell carcinomas of the h...

Full description

Bibliographic Details
Main Authors: Dongmei Ye, Xueyan Liang, Xiaoyu Chen, Yan Li
Format: Article
Language:English
Published: Nature Portfolio 2024-03-01
Series:Scientific Reports
Subjects:
Nivolumab
Ipilimumab
Head and neck squamous cell carcinoma
Cetuximab
EXTREME
Online Access:https://doi.org/10.1038/s41598-024-57277-7

Similar Items

Similar Items